| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.40(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
12,005 |
99,487 |
197,241 |
249,694 |
| Total Sell Value |
$596,362 |
$4,824,734 |
$8,130,065 |
$10,494,293 |
| Total People Sold |
2 |
8 |
9 |
12 |
| Total Sell Transactions |
3 |
12 |
19 |
35 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,208 |
14,309 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
19,084 |
|
- |
|
| Kassberg Thomas Richard |
CBO & EVP |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
91,675 |
|
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
39,138 |
|
- |
|
| Huizenga Theodore Alan |
SVP, Controller and PAO |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
800 |
16,785 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,434 |
100,523 |
|
- |
|
| Bedrosian Camille L |
EVP and Chief Medical Officer |
• – – |
2019-10-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,437 |
26,239 |
|
- |
|
| Hogenhuis Wladimir |
Chief Operating Officer |
• – – |
2019-10-04 |
4 |
D |
$44.52 |
$57,742 |
D/D |
(1,297) |
18,703 |
|
- |
|
| Sharp Shalini |
CFO & Executive Vice President |
• – – |
2019-09-16 |
4 |
OE |
$0.81 |
$176,317 |
D/D |
31,843 |
99,089 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2019-09-11 |
4 |
B |
$43.63 |
$218,150 |
D/D |
5,000 |
472,479 |
2.81 |
- |
|
| Pinion John Richard |
See Remarks |
• – – |
2019-07-16 |
4 |
D |
$59.17 |
$38,401 |
D/D |
(649) |
37,704 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2019-07-06 |
4 |
D |
$59.51 |
$15,473 |
D/D |
(260) |
13,101 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-06-24 |
4 |
AS |
$61.50 |
$75,399 |
D/D |
(1,226) |
17,650 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-06-21 |
4 |
AS |
$63.01 |
$93,822 |
D/D |
(1,489) |
18,876 |
|
- |
|
| Parschauer Karah Herdman |
EVP and General Counsel |
• – – |
2019-06-20 |
4 |
D |
$63.48 |
$41,199 |
D/D |
(649) |
20,365 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2019-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
3,500 |
13,361 |
|
- |
|
| Harris Erik |
EVP & Chief Commercial Officer |
• – – |
2019-06-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,861 |
|
- |
|
| Narachi Michael |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,750 |
|
- |
|
| Siegall Clay B |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,750 |
|
- |
|
| Welch Daniel G |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,750 |
|
- |
|
| Fust Matthew K |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
14,750 |
|
- |
|
| Suliman Shehnaaz |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
3,000 |
|
- |
|
| Dunsire Deborah |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
7,875 |
|
- |
|
| Ekman Lars |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
9,750 |
|
- |
|
| Aliski William |
Director |
– • – |
2019-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
47,924 |
|
- |
|
628 Records found
|
|
Page 13 of 26 |
|
|
0.37 (0.89%) 
